NCT04349800View on ClinicalTrials.gov

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
Hereditary Angioedema
Interventions
DRUG

KVD900

Active

DRUG

Placebo to KVD900

Placebo

Trial Locations (1)

Unknown

KalVista Investigative Site, Wales

Sponsors
All Listed Sponsors
lead

KalVista Pharmaceuticals, Ltd.

INDUSTRY